Silins R A, Marlin G E
Aust N Z J Med. 1985 Apr;15(2):230-4. doi: 10.1111/j.1445-5994.1985.tb04014.x.
Domiciliary treatment with terbutaline by wet nebulisation (5 mg, four times daily) was compared with placebo in a double-blind study over four consecutive periods, each of seven days duration, in eight patients with severe airflow limitation due to chronic bronchitis and emphysema. Lung function tests performed at the conclusion of each treatment period showed small but significant improvements in FEV1 before and after 500 micrograms of terbutaline by metered dose inhaler (MDI), with reductions in functional residual capacity and residual volume for terbutaline compared with placebo. Morning and evening peak expiratory flow rate recordings were greater and there was a significant reduction in the use of terbutaline by MDI during the terbutaline treatment. Three patients were unable to complete the placebo treatment because of excessive symptoms. Analysing all individual results, only one patient appeared not to benefit from nebulised terbutaline, while the preference rating for the other seven patients was significantly in favour of terbutaline.
在一项双盲研究中，对8例因慢性支气管炎和肺气肿导致严重气流受限的患者，连续四个为期7天的阶段，将特布他林雾化吸入（5毫克，每日4次）的居家治疗与安慰剂进行比较。在每个治疗阶段结束时进行的肺功能测试显示，使用定量吸入器（MDI）吸入500微克特布他林前后，第一秒用力呼气容积（FEV1）有微小但显著的改善，与安慰剂相比，特布他林使功能残气量和残气量减少。早晚的呼气峰值流速记录更高，并且在特布他林治疗期间，MDI使用特布他林的量显著减少。3例患者因症状过重无法完成安慰剂治疗。分析所有个体结果，只有1例患者似乎未从雾化特布他林中获益，而其他7例患者的偏好评分明显倾向于特布他林。
